The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.

doi:10.1016/j.jtho.2020.05.019

Article

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2020

Sholl Lynette M, Hirsch Fred R, Hwang David, Botling Johan, Lopez-Rios Fernando, Bubendorf Lukas, Mino-Kenudson Mari, Roden Anja C, Beasley Mary Beth, Borczuk Alain, Brambilla Elisabeth, Chen Gang, Chou Teh-Ying, Chung Jin-Haeng, Cooper Wendy A, Dacic Sanja, Lantuejoul Sylvie, Jain Deepali, Lin Dongmei, Minami Yuko, Moreira Andre, Nicholson Andrew G, Noguchi Masayuki, Papotti Mauro, Pelosi Giuseppe, Poleri Claudia, Rekhtman Natasha, Tsao Ming-Sound, Thunnissen Erik, Travis William, Yatabe Yasushi, Yoshida Akihiko, Daigneault Jillian B, Zehir Ahmet, Peters Solange, Wistuba Ignacio I, Kerr Keith M, Longshore John W

Abstract excerpt

Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients with NSCLC and have led to unprecedented improvements in response rates and survival in a subset of patients with this fatal disease. However, the available therapies work only for a minority of patients, are associated with substantial societal cost, and may lead to considerable immune-related adverse events. Therefore,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.

Abstract excerpt

Topics

Related research